TOKYO, May 12 (Pulse News Wire) – Nipro Corporation (8086.T) reported foreign exchange losses, grants income, and asset impairment charges for its fiscal year ending March 31, 2026. For the fiscal year ended March 31, 2026, the company recorded a foreign exchange loss of ¥4.191 billion due to fluctuations in foreign currency markets.
Additionally, the company recognized special income of ¥4.073 billion from government grants related to the construction of a manufacturing facility for cefmen antibiotics at Nipro Pharma's Omi Plant, which was approved under the Ministry of Economy, Trade and Industry’s domestic investment promotion program. Furthermore, the company applied direct reduction accounting treatment resulting in an asset impairment charge of ¥3.870 billion.
This charge was incurred due to the grant receipt and accounted for as a special loss. These adjustments are reflected in the company's unaudited consolidated earnings release for the fiscal year ended March 31, 2026.
🟢 Confidence: High AI-translated content.